These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 28109184)

  • 41. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study.
    Zhou J; Zhang G; Chang C; Chou OHI; Lee S; Leung KSK; Wong WT; Liu T; Wai AKC; Cheng SH; Zhang Q; Tse G
    Acta Diabetol; 2022 May; 59(5):697-709. PubMed ID: 35112189
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus.
    Tschöpe D; Bramlage P; Schneider S; Gitt AK
    Diab Vasc Dis Res; 2016 Jan; 13(1):2-12. PubMed ID: 26567123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults.
    Zullo AR; Smith RJ; Gutman R; Kohler B; Duprey MS; Berry SD; Munshi MN; Dore DD
    J Am Geriatr Soc; 2021 Oct; 69(10):2923-2930. PubMed ID: 34291453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Obes Metab; 2017 Jun; 19(6):831-841. PubMed ID: 28116795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
    Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
    BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
    Svanström H; Ueda P; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
    Lancet Diabetes Endocrinol; 2019 Feb; 7(2):106-114. PubMed ID: 30527909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
    Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.
    He S; Qian X; Chen Y; Shen X; Zhang B; Chen X; Xu X; Li G
    J Diabetes Res; 2021; 2021():5534387. PubMed ID: 34222493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
    Douros A; Dell'Aniello S; Yu OHY; Suissa S
    Diabetes Obes Metab; 2020 Feb; 22(2):254-262. PubMed ID: 31596043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study.
    Wang H; Cordiner RLM; Huang Y; Donnelly L; Hapca S; Collier A; McKnight J; Kennon B; Gibb F; McKeigue P; Wild SH; Colhoun H; Chalmers J; Petrie J; Sattar N; MacDonald T; McCrimmon RJ; Morales DR; Pearson ER;
    Diabetes Care; 2023 May; 46(5):967-977. PubMed ID: 36944118
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
    Shin H; Schneeweiss S; Glynn RJ; Patorno E
    Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
    Komamine M; Kajiyama K; Ishiguro C; Uyama Y
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1166-1174. PubMed ID: 31338935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea.
    Yang H; Choi E; Park E; Na E; Chung SY; Kim B; Han SY
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00910. PubMed ID: 35005849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes of second-line oral antidiabetic drugs in persons with young-onset type 2 diabetes.
    Yen FS; Cheng-Chung Wei J; Liu JS; Hsu CC; Hwu CM
    Diabetes Res Clin Pract; 2021 Jul; 177():108928. PubMed ID: 34171441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
    Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
    Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
    Wang J; Wu HY; Chien KL
    Diabetes Metab; 2022 May; 48(3):101299. PubMed ID: 34728339
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incretin-based therapy and the risk of diabetic foot ulcers and related events.
    Werkman NCC; Driessen JHM; Klungel OH; Schaper NS; Souverein PC; Stehouwer CDA; Nielen JTH
    Diabetes Obes Metab; 2024 Sep; 26(9):3764-3780. PubMed ID: 38951877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.